S&P 500
(1.36%) 5 132.90 points
Dow Jones
(1.29%) 38 718 points
Nasdaq
(2.10%) 16 174 points
Oil
(-0.75%) $78.36
Gas
(5.06%) $2.14
Gold
(0.06%) $2 311.10
Silver
(-0.41%) $26.72
Platinum
(0.37%) $966.15
USD/EUR
(-0.36%) $0.929
USD/NOK
(-1.23%) $10.86
USD/GBP
(-0.12%) $0.797
USD/RUB
(0.37%) $91.47

实时更新: Kaken Pharmaceutical Co., [4521.T]

交易所: JPX 部门: Healthcare 工业: Drug Manufacturers—Specialty & Generic
Upcoming Earnings Alert

4 days till quarter result
(bmo 2024-05-07)

Expected move: +/- 0.00%

最后更新时间2 May 2024 @ 14:15

0.03% ¥ 3 478.00

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 14:15):

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation...

Stats
今日成交量 108 100
平均成交量 124 575
市值 131.71B
EPS ¥0 ( 2024-02-05 )
下一个收益日期 ( ¥0 ) 2024-05-07
Last Dividend ¥75.00 ( 2023-03-30 )
Next Dividend ¥0 ( N/A )
P/E 44.25
ATR14 ¥1.086 (0.03%)

音量 相关性

長: -0.07 (neutral)
短: -0.70 (moderate negative)
Signal:(42.479) Neutral

Kaken Pharmaceutical Co., 相关性

10 最正相关
10 最负相关

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kaken Pharmaceutical Co., 相关性 - 货币/商品

The country flag 0.61
( weak )
The country flag 0.24
( neutral )
The country flag -0.18
( neutral )
The country flag 0.68
( moderate )
The country flag -0.48
( neutral )
The country flag -0.82
( strong negative )

Kaken Pharmaceutical Co., 财务报表

Annual 2022
营收: ¥72.98B
毛利润: ¥39.56B (54.20 %)
EPS: ¥144.79
FY 2022
营收: ¥72.98B
毛利润: ¥39.56B (54.20 %)
EPS: ¥144.79
FY 2022
营收: ¥76.03B
毛利润: ¥41.58B (54.68 %)
EPS: ¥251.43
FY 2021
营收: ¥74.98B
毛利润: ¥40.91B (54.56 %)
EPS: ¥347.37

Financial Reports:

No articles found.

Kaken Pharmaceutical Co., Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
¥75.00
(N/A)
¥0
(N/A)
¥75.00
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)
¥0
(N/A)

Kaken Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 2.36 - Decrease likely (52.76%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend ¥7.50 2001-03-27
Last Dividend ¥75.00 2023-03-30
Next Dividend ¥0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 46 --
Total Paid Out ¥1 874.70 --
Avg. Dividend % Per Year 0.00% --
Score 3.32 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 2.36
Div. Directional Score 6.18 --
Next Divdend (Est)
(2024-07-03)
¥0 Estimate 1.26 %
Dividend Stability
0.10 Bad
Dividend Score
3.32
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
6656.T Ex Dividend Junior 2024-04-26 Annually 0 0.00%
5989.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%
4681.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
3925.T Ex Dividend Junior 2024-03-28 Annually 0 0.00%
3156.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%
2121.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
9010.T Ex Dividend Knight 2024-03-28 Annually 0 0.00%
8584.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
7908.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%
7065.T Ex Dividend Junior 2023-08-30 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.04111.5009.1810.00[0 - 0.5]
returnOnAssetsTTM0.01761.2009.4110.00[0 - 0.3]
returnOnEquityTTM0.02141.500-0.873-1.310[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM5.640.80010.008.00[1 - 3]
quickRatioTTM4.640.80010.008.00[0.8 - 2.5]
cashRatioTTM2.631.50010.0010.00[0.2 - 2]
debtRatioTTM0.0229-1.5009.62-10.00[0 - 0.6]
interestCoverageTTM248.721.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM145.292.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM145.292.0010.0010.00[0 - 20]
debtEquityRatioTTM0.0275-1.5009.89-10.00[0 - 2.5]
grossProfitMarginTTM0.5391.0004.354.35[0.2 - 0.8]
operatingProfitMarginTTM0.06211.000-0.758-0.758[0.1 - 0.6]
cashFlowToDebtRatioTTM1.4291.0003.173.17[0.2 - 2]
assetTurnoverTTM0.4280.800-0.478-0.382[0.5 - 2]
Total Score10.01

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM44.411.0005.620[1 - 100]
returnOnEquityTTM0.02142.50-0.561-1.310[0.1 - 1.5]
freeCashFlowPerShareTTM145.292.0010.0010.00[0 - 30]
dividendYielPercentageTTM4.311.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM145.292.0010.0010.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.0471.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.07631.000-0.5920[0.1 - 0.5]
Total Score2.36

Kaken Pharmaceutical Co.,

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。